We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer ...

We played a major role in revealing the biochemical steps of the RAS-RAF-MAP kinase pathway. We identified one of the major ...

Through studies that were amongst the largest of their kind, we identified several genes involved in breast and/or ovarian cancer predisposition such as CHEK2, BRIP1, ATM, PALB2, RAD51C and RAD51D.

We identified many of the cancer-causing chemicals in cigarette smoke and coal tar – including the first pure carcinogen ever to be isolated.

We were the first in Europe to develop chemotherapeutic agents. We discovered, and with The Royal Marsden developed, the chemotherapy drugs busulfan, chlorambucil, melphalan and carboplatin, which are ...

The ICR’s dedicated breast cancer research centre was launched 25 years ago. Robbie Lockyer explores the history of the centre and how our scientists working in it have made a difference for patients.

DJ and music promoter, Godfrey Fletcher, was diagnosed with prostate cancer in 2015 at the age of 47, shortly after his father was also diagnosed with the same disease. Since then, Godfrey has made it ...

We applied the principle of synthetic lethality to discover a novel strategy for cancer treatment for patients with BRCA1 or ...

PI3 kinase is a lipid signalling enzyme which plays a key role in the development and progression of many cancers as a result ...

Multiple myeloma (MM) affects over 5,500 people annually in the UK, with a 5-year survival rate below 50% in advanced stages. Resistance to therapies is driven by transcriptional addiction, where ...